Updates are available Correction dated 2021-03-30
Click to view Correction: https://doi.org/10.1038/s41391-021-00358-9
-
Authors
Spratt, Daniel E. https://orcid.org/0000-0002-5973-4741
Shore, Neal
Sartor, Oliver https://orcid.org/0000-0002-8777-7343
Rathkopf, Dana
Olivier, Kara
- License Information
-
More Information
Article History
Received: 5 September 2020
Revised: 12 January 2021
Accepted: 20 January 2021
First Online: 18 February 2021
Change Date: 30 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-021-00358-9
Compliance with ethical standards
:
: DS has received grants from Janssen and personal fees from Janssen, Blue Earth, and AstraZeneca. NS has received personal fees from Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Bayer, Dendreon, Ferring, Fergene, Janssen, Merck, Myovant, Nymox, Pfizer, Sanofi, Tolmar, Boston Scientific, and MDx Health. OS has received personal fees from AAA, Astellas, AstraZeneca, Bayer, Blue Earth diagnostics, Bravarin Nordic, Bristol-Myers Squibb, Clovis, Constellation, Dendreon, EMD Serono, Endocyte, Pfizer, Progenics, Sanofi, Merck, Myriad, Noria Therapeutics, Noxopaharm, Point Biopharma, Tenebio, Theragnostics, Telix, Clarity Pharmaceuticals, Novartis, and Janssen, and has received grants from AAA, AstraZeneca, Bayer, Endocyte, Progenics, Sanofi, Innocrin, Invitae, Merck, Novartis, Sotio and Janssen. KO reports consulting for Exelixis. DR declares no conflict of interest.
